Helen X. Chen MD

Helen Chen joined the Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI) in 2000. She currently serves as Associate Chief of the Investigational Drug Branch (IDB) Section III, which focuses on the clinical development of antibody-based therapeutics, active immunotherapies, MAPK and RTK inhibitors as well as antiangiogenic agents.

She has also been closely involved in NCI’s efforts on novel agent combinations and is member of the NCI Experimental Therapeutics Committee.